Moderna, Inc. (MRNA)
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2.0 billion and outlined its pipeline milestones for 2026-28, with the company continuing to focus on Covid-19 as its near-term revenue driver. In its annual letter, Moderna highlighted that its Covid vaccines remain central to 2026, with the mNEXSPIKE vaccine representing roughly 24% of all US retail Covid vaccinations in 2025 and nearly one-third of vaccinations among adults aged 65 and older.
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna shares are down almost 28% in the year to date, trading just shy of $30 on Friday morning.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
Moderna (MRNA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRNA broke through the 50-day moving average, which suggests a short-term bullish trend.
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average
Moderna (MRNA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRNA crossed above the 20-day moving average, suggesting a short-term bullish trend.
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership
A major vaccine producer came under pressure following a report federal health regulators plan to tighten vaccine approval rules. Meanwhile, an agreement with the world's most valuable company bolstered a software firm whose products help customers design and test semiconductors.
